However, some studies have shown that there may also be a temporary increase of PSA in the early stage of abiraterone treatment, that is “PSA flare.”[10] There was no increase of PSA in this patient after the therapy of abiraterone combined with prednisone, which may be related to the reduction of tumor load by concurrent radiotherapy. The gene discussed is KLK3; the disease is neoplasm.